Rheumatology Book

http://www.fpnotebook.com/

AbataceptAka: CTLA4-Ig

Advertisement

  1. Mechanism
    1. Extracellular CTLA4 fused to Fc of IgG1
    2. Inhibits CD28 to CD80/CD66 binding
    3. Increases T-cell activation threshold and inhibits T-Cell proliferation
  2. Dosing
    1. IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
    2. Initial: 0, 2 and 4 months and then every 4 months
  3. Indications
    1. Refractory Rheumatoid Arthritis
  4. Contraindications
    1. Do not use with TNF antagonist agent, and probably Anankira
    2. Live virus vaccine within the last 3 months

abatacept (C1619966)

ConceptsAmino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSHC468566
Englishabatacept
Spanishabatacept
Parent ConceptsAntirheumatic Agents (C0003191), Fusion protein (C0162768)
SourcesMSH, MTHSPL, NCI, RXNORM, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree